185 related articles for article (PubMed ID: 34623640)
1. Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
Meng A; Humeniuk R; Jürgensmeier JM; Hsueh CH; Matzkies F; Grant E; Truong H; Billin AN; Yu H; Feng J; Kwan E; Tarnowski T; Nelson CH
Clin Pharmacol Ther; 2022 Feb; 111(2):416-424. PubMed ID: 34623640
[TBL] [Abstract][Full Text] [Related]
2. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection.
Byun JY; Koh YT; Jang SY; Witcher JW; Chan JR; Pustilnik A; Daniels MJ; Kim YH; Suh KH; Linnik MD; Lee YM
Sci Rep; 2021 Sep; 11(1):18671. PubMed ID: 34548595
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
5. Tirabrutinib: First Approval.
Dhillon S
Drugs; 2020 Jun; 80(8):835-840. PubMed ID: 32382949
[TBL] [Abstract][Full Text] [Related]
6. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Yu H; Truong H; Mitchell SA; Liclican A; Gosink JJ; Li W; Lin J; Feng JY; Jürgensmeier JM; Billin A; Xu R; Patterson S; Pagratis N
SLAS Discov; 2018 Oct; 23(9):919-929. PubMed ID: 30011241
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
8. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
[TBL] [Abstract][Full Text] [Related]
9. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
[TBL] [Abstract][Full Text] [Related]
10. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Leu JH; Miao X; Shalayda K; Coe KJ; Kahnt A; Wu B; Schnarr M; Franks C; Devlin J; Yang TY; Palmer JA; Zhang M; Zhou H; Van Damme W; Smets S; Aguilar Z; Chaplan SR
Clin Pharmacol Drug Dev; 2023 Jun; 12(6):611-624. PubMed ID: 37125450
[TBL] [Abstract][Full Text] [Related]
15. A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis.
Liu YT; Ding HH; Lin ZM; Wang Q; Chen L; Liu SS; Yang XQ; Zhu FH; Huang YT; Cao SQ; Yang FM; Song ZL; Ding J; Geng MY; Xie H; Zhang A; He SJ; Zuo JP
Acta Pharmacol Sin; 2021 Oct; 42(10):1653-1664. PubMed ID: 33441995
[TBL] [Abstract][Full Text] [Related]
16. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Esfandiari E; Chen M; Smithson G; Blair D; Faessel H; Wagner J; Mclean L; Fedyk ER
Clin Transl Sci; 2021 May; 14(3):820-828. PubMed ID: 33650758
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Ou YC; Liu L; Tariq B; Wang K; Jindal A; Tang Z; Gao Y; Sahasranaman S
Clin Transl Sci; 2021 Mar; 14(2):764-772. PubMed ID: 33306268
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]